<Back to Therapeutic Areas

<Back to Menu

Infectious Diseases

Pathophysiology of COVID-19 (2:25)

An Evolving Target: Variants of SARS-Cov-2 (5:49)

Monoclonal Antibodies in COVID-19 (4:15)

IME/CME for HCPs

GSK identifies and funds innovative, high-quality, independent third-party educational initiatives that are designed to close healthcare professional (HCP) educational, quality, and performance gaps to improve patient health and quality of life. GSK provides financial support for independent medical education (IME) for HCPs, including certified continuing medical education (CME, CE), with a grant.

Educational providers are fully compliant with the ACCME (and other nationally recognized accrediting body) standards for commercial support and design and deliver all activities (including content, faculty, speakers, and educational materials) independent from GSK control, influence, and involvement.

These initiatives offer opportunities for continual learning regarding educational topics and are free for learners to access. For more information about any of these initiatives, please click the link to be directed to the educational provider's website. All questions about these activities should be directed to the educational provider listed for each activity, not to GSK, as these are not GSK initiatives.


COVID19 Keeping Up with a Moving Target Viral Variants

Expiration Date: December 02, 2022

Educational Provider: Postgraduate Institute for Medicine


Neutralizing Monoclonal Antibodies for Patients with COVID19

Expiration Date: October 15, 2022

Educational Provider: AKH, Inc., Advancing Knowledge in Healthcare


Role of Monoclonal Antibodies in Patients with COVID19

Expiration Date: October 21, 2022

Educational Provider: Pro CE, LLC


Monoclonal Antibodies in Treatment of at Risk Patients With COVID19

Expiration Date: November 09, 2022

Educational Provider: The France Foundation


Minimizing Risks from COVID19

Expiration Date: December 31, 2022

Educational Provider: UMA Education, Inc. dba Global Education Group


The GSK Medical Team attends several key medical congresses. Please visit us at our scientific booths to view our scientific information.

Meet Us

NHIA | Mar 12-16, 2022 | Nashville, TA

Pri-Med Southwest | Apr 5-7, 2022 | Houston, TX

AAEM | Apr 23-27, 2022 | Baltimore, MD

ACP Internal Medicine Meeting | Apr 28-30, 2022 | Chicago, IL

UCA | Apr 30-May 4, 2022 | Las Vegas, NV

ATS | May 13-18, 2022 | San Francisco, CA

AAFP | Sep 20-24, 2022 | Washington DC

ACEP | Oct 1-4, 2022 | San Francisco, CA

IDWeek | Oct 19-23, 2022 | Washington DC

ASHP | Dec 4-8, 2022 | Las Vegas, NV

Sotrovimab (Emergency Use Authorization)

Fact Sheet for Healthcare Providers
Fact Sheet for Patients, Parents, and Caregivers (English)
Fact Sheet for Patients, Parents, and Caregivers (Spanish)
FDA Letter of Authorization for EUA
Material Safety Data Sheets
How Supplied/Storage & Handling arrow-down arrow-up

How Supplied:

  • Sotrovimab injection 500 mg (62.5 mg/mL) is a sterile, preservative-free, clear, colorless or yellow to brown solution supplied in a carton containing one single-dose glass vial with a rubber vial stopper (not made with natural rubber latex) and a flip-off cap (NDC 0173-0901-86).

Storage & Handling:

  • Sotrovimab is preservative-free. Discard unused portion.
  • Store unopened vials refrigerated at 2°C to 8°C (36°F to 46°F) in original carton. Do not freeze or shake. Protect from light.
  • The solution of sotrovimab in the vial is preservative-free and requires dilution prior to administration. The diluted infusion solution of sotrovimab should be administered immediately. If immediate administration is not possible, store the diluted infusion solution for up to 24 hours at refrigerated temperature (2°C to 8°C [36°F to 46°F]) or up to 6 hours at room temperature (up to 25°C [up to 77°F]) including transportation and infusion time. If refrigerated, allow the infusion solution to equilibrate to room temperature for approximately 15 minutes prior to administration.

Important update: Sotrovimab is currently not authorized in any US region, due to the prevalence of SARS-CoV-2 Omicron BA.2 sub-variant, until further notice by the FDA. FDA's statement and any updates on the authorization will be available on the FDA website.

GSK Medical Team attends several key medical congresses. You can access presentations, posters, and symposia material below.

IDWeek 2022

October 19-23, 2022 | Washington, DC

ECCMID 2022

April 23-26, 2022 | Lisbon, Portugal

AMCP 2022

March 29 - April 1, 2022 | Chicago

CROI 2022

February 12-16, 2022 | Virtual

If you have a question, please contact the GSK COVID Contact Center.

Phone
9 AM - 6 PM ET, Monday - Friday, with after hours pager service available

View our ongoing, innovative research in infectious diseases.

Sotrovimab Phase II Phase III Phase IV

COMET-PEAK: Safety, Tolerability, and Pharmacokinetics of Second Generation VIR-7831 in Non-hospitalized Patients with mild to Moderate COVID-19

NCT04779879

COMET-TAIL: Intramuscular Sotrovimab (VIR-7831) for Mild/Moderate COVID-19.

NCT04913675

COMET-PACE: Pharmacokinetics, Pharmacodynamics, and Safety of Single-dose Sotrovimab in High-risk Pediatric Participants With Mild to Moderate COVID-19

NCT05124210
  • *Sotrovimab is being developed in a collaboration between GSK and Vir Biotechnology
Gepotidacin Phase I Phase II Phase III

A Study to Evaluate Efficacy and Safety of Gepotidacin in the Treatment of Uncomplicated Urinary Tract Infection

NCT04020341

Comparative Study to Evaluate Efficacy and Safety of Gepotidacin to Nitrofurantoin in Treatment of Uncomplicated Urinary Tract Infection

NCT04187144

A Study Evaluating Efficacy and Safety of Gepotidacin Compared With Ceftriaxone Plus Azithromycin in the Treatment of Uncomplicated Urogenital Gonorrhea

NCT04010539

Antibody Collaborations (0.27)

COVID-19 Immunology (0.29)

What are Variants (0.44)

What is Antibody Therapy (0.42)